Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications - Wikidata - awgldk - TriplyDB

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

http://www.wikidata.org/entity/Q24617091

about

The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells Cellular protection using Flt3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity.Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients Dissect: detection and characterization of novel structural alterations in transcribed sequences Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Microenvironmental hypoxia regulates FLT3 expression and biology in AML.A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells Distinct signaling programs control human hematopoietic stem cell survival and proliferation.Current findings for recurring mutations in acute myeloid leukemia Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells.Targeting FLT3 to treat leukemia.Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.Emerging cell cycle inhibitors for acute myeloid leukemia.Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3.Mutated genes and driver pathways involved in myelodysplastic syndromes—a transcriptome sequencing based approach.Whole-Exome Sequencing of ETV6/RUNX1 in Four Childhood Acute Lymphoblastic Leukaemia Cases FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia.An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.Internal tandem duplication and tyrosine kinase domain mutations in FLT3 alter the response to daunorubicin in Ba/F3 cells.Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death.Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.

P2860

Q26799596-C24EED89-2E93-4F1B-AA2D-FE74F4B03920 Q27027207-06391BDD-D8FD-402A-A869-C041A8A2A61D Q33404677-231CB77D-FC94-4EA4-80F6-3097D83B5C9C Q33641201-0C571D71-5D66-40DD-AA6C-30EDB3DEFA0A Q33710062-D3C7DE53-63A2-4119-8E66-60A47E3142E4 Q33749036-A5B270AE-E1FE-43AF-AE85-BCE776971C2E Q33778374-09CF616A-455F-4FB6-B2F3-AAE746E51A58 Q33815665-DE46125A-08E2-4A53-B515-CDD58ED30ADD Q33913465-A8F19405-6807-4B79-BBA2-6BC1FF573A59 Q34307027-AA311546-F78A-4BEE-8E4D-CCF3AB25ED3A Q34502608-76E870AC-064D-4BB9-93E6-7EFF4B51F916 Q35150284-E5A09E55-D750-4E02-BFA7-4F016C6F7D06 Q35873466-66C030EB-4177-43D3-8288-D5D49D38B489 Q36022127-47B1194A-C093-4372-A050-7DEBE33C4B12 Q36165726-240ACE7B-9AA9-4495-A44F-E202210444B5 Q36322776-76BB1B61-13EC-472D-855B-1D757B2689AE Q36329436-FE0F1C6D-C6DC-4162-9756-986CCC4F4BEC Q36408534-0D3DAA51-CB66-47C2-A24E-9C878ACFD09F Q36758390-B775081C-35D3-4B0C-A7AD-DD3732BA5D45 Q37365776-0E7C2F53-62C3-4B3B-8245-BF2AC4643789 Q37535249-BE704A9D-3AB0-4C3D-B59E-247F053B1234 Q37610391-00CEDD30-F144-4B5A-81D7-A9E1C287845C Q37932085-28B08CD4-C203-40F5-8EF1-B8C850F6320F Q38180461-1EC3386B-92F8-41F3-9343-7A0579B4F799 Q38251339-383864C5-A0A8-439B-A29A-852C3497E527 Q38673618-A33688E7-FD12-4169-827E-CE736DB70B71 Q38785380-70873681-0050-4F0E-B14F-706B5C3A6A17 Q39105964-A5D0C920-F062-48EA-A48B-A4A0C8586124 Q39284759-78B1DADB-46F4-4CC1-B19E-8D6C6EF00DB2 Q40902348-A78957DF-CDD3-4709-A3B4-FE7927D171F5 Q40982056-218DC478-BE06-48D6-918D-88DA10E5587B Q41230366-F0081797-52DE-48B6-9BB1-8557DDD1DB04 Q41819724-C4D67D5B-6BA9-4499-AEA7-2EC01C4A0636 Q41908916-20D4690B-D9ED-4127-B383-7921780B649F Q42005573-2DD2DA7C-8C25-414B-A882-A7279B9CA0EE Q42177447-BFD5065B-A5F9-4405-9B81-F494C9E327A4 Q42385341-EEEA5137-4C18-4585-8DD6-D9B6BCE23EBE Q48158060-ADBFE797-FE88-40D1-8170-CFAB75BF3D6E Q48159392-84CC294E-0B1C-4894-86DC-4076A45651EF Q48282223-D9B21D2D-0421-4758-A325-A602B66A8EDB

P2860

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

http://www.wikidata.org/entity/Q24617091

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Downstream molecular pathways ...... y and therapeutic implications

@ast

Downstream molecular pathways ...... y and therapeutic implications

@en

Downstream molecular pathways ...... y and therapeutic implications

@nl

type

label

Downstream molecular pathways ...... y and therapeutic implications

@ast

Downstream molecular pathways ...... y and therapeutic implications

@en

Downstream molecular pathways ...... y and therapeutic implications

@nl

prefLabel

Downstream molecular pathways ...... y and therapeutic implications

@ast

Downstream molecular pathways ...... y and therapeutic implications

@en

Downstream molecular pathways ...... y and therapeutic implications

@nl

P1433

Q24617091-F3A53141-EF3C-4D7B-9158-DD6A310B3E43

P1476

Q24617091-DCB6487C-76A6-4C67-8B7D-8D60E6E6A958

P2093

Q24617091-2B6AA5DF-4E17-4012-B859-093499551382

P275

Q24617091-AB2FCEF2-2DF4-49D8-85DB-5516D2EF7D19

P2860

Q24617091-0042B375-1B04-4C23-A1C3-DFBE5D1B200E

Q24617091-00AC449F-124B-4F68-B574-9EAF56E6BE55

Q24617091-0313D2DB-77D9-4390-AACF-9470308730B7

Q24617091-073B8AFD-DB4E-4D4B-8825-6E06751E0881

Q24617091-0B186D7A-5FA7-41A0-BB8B-3E582EB4A7C9

Q24617091-0D85D0CF-887A-4F03-B384-29F2A38F16B1

Q24617091-0D916824-54E8-4188-93D3-D1FAC81114B2

Q24617091-0DF549C0-46B4-49CB-AE28-D7C9BBAF10B9

Q24617091-0E346707-F71F-495C-8859-B69F1E629503

Q24617091-0F6F73DB-1726-457D-AC68-D9596AC46297

P2888

Q24617091-2069DA59-0905-45EB-9CD3-D847387FDFC8

P304

Q24617091-C9FFD965-27F5-454F-892C-453B3516362F

P31

Q24617091-1836A970-B578-41AD-8C7B-AA08052F5007

P3181

Q24617091-CB47B8BE-3342-46F4-BCD4-C00C36C9FF02

P356

Q24617091-BA3617DC-2584-4F35-9110-B3F3E6D38207

P407

Q24617091-4DF388F0-22F5-464F-ABD5-51E21757355F

P433

Q24617091-5B1F0EC2-8EFC-4999-A67D-A8E933811173

P478

Q24617091-CC7E2127-8F12-489F-9125-0F68C3401B45

P50

Q24617091-B9D0858A-8FA3-47B5-B41E-98004A878EFD

P5008

Q24617091-283826B8-A895-49C1-9837-74A90C8E4FC2

P577

Q24617091-A0B6C464-AB24-4FD0-9DDE-3DADC93A4281

P5875

Q24617091-A0733FA3-6704-4635-8461-CC6D3D062388

P6179

Q24617091-510F223D-1B52-4A66-B05B-3166593ACB79

P698

Q24617091-9A43FD05-456D-4E72-8016-FAA22DEB55AE

P921

Q24617091-159FB701-3323-4549-A003-A398BDA89228

Q24617091-2DBC5CD9-4314-432F-BBEB-87540C008279

Q24617091-406DC95C-34A9-40F3-B50C-9B922F90C222

Q24617091-58AF57A3-FD82-481F-8CA1-D3C106CFF33C

Q24617091-7A063898-77FE-4F0E-8CA1-9A3F7E03AF8F

Q24617091-9FF4CC85-8D54-4195-8FAC-7953FC2BABCC

Q24617091-D7031368-231C-4C91-BEFA-AF529E29C13F

Q24617091-E8D4433C-575C-4E14-8651-2922CAF45F42

Q24617091-EBF46F24-C7AD-469A-BC29-2088C98A4A21

P932

Q24617091-778D7F23-754C-4998-B0AD-201229F1BCEA

P3181

P356

P1433

Journal of Hematology & Oncology

P1476

Downstream molecular pathways ...... y and therapeutic implications

@en

P2093

Shinichiro Takahashi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells

Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors

Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells

The role of FLT3 in haematopoietic malignancies

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

Cell signaling by receptor tyrosine kinases

DNMT3A Mutations in Acute Myeloid Leukemia

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

P2888

P304

13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4778767

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1756-8722-4-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Shinichiro Takahashi

P5008

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50938791

http://www.w3.org/2001/XMLSchema#string

P6179

1005792756

http://www.w3.org/2001/XMLSchema#string

P698

21453545

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

acute myeloid leukemia

regulation of gene expression

membrane proteins

proto-oncogene proteins

neoplasm proteins

P932

3076284

http://www.w3.org/2001/XMLSchema#string